Which patients with rheumatoid arthritis, spondyloarthritis, or juvenile idiopathic arthritis receive TNF-α antagonists in France? The CORPUS cohort study

Clinical and Experimental Rheumatology

Volumn 33, Issue 5, 2015, Pages 602-610

  Saraux, Alain ^a   Benichou, Jacques ^b   Guillevin, Loic ^c   Idbrik, Latifa ^d,e   Job Deslandre, Chantal ^c   Sibilia, Jean ^f   Soudant, Marc ^g   Wendling, Daniel ^h,i   Guillemin, Francis ^g  

^a BREST UNIVERSITY HOSPITAL   (France)

^b ROUEN UNIVERSITY HOSPITAL   (France)

^c Institut Cochin   (France)

^d CHU NANCY BRABOIS   (France)

^e INSERM   (France)

^f HÔPITAL DE HAUTEPIERRE   (France)

^g UNIVERSITY HOSPITAL OF NANCY   (France)

^h UNIVERSITY HOSPITAL OF BESANÇON   (France)

ⁱ Hôpital Saint Jacques   (France)

Author keywords

Biologics; DMARDs; Juvenile idiopathic arthritis; Methotrexate; Rheumatoid arthritis; Spondylarthritis

Indexed keywords

ADALIMUMAB; C REACTIVE PROTEIN; ETANERCEPT; INFLIXIMAB; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; ANTIRHEUMATIC AGENT; IMMUNOLOGIC FACTOR; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DAS28; DISEASE ACTIVITY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FOLLOW UP; FRANCE; GEOGRAPHIC DISTRIBUTION; HEALTH ASSESSMENT QUESTIONNAIRE; HEALTH INSURANCE; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; POPULATION RESEARCH; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; REIMBURSEMENT; RHEUMATOID ARTHRITIS; SPONDYLARTHRITIS; SPONDYLOARTHROPATHY; TREATMENT DURATION; TREATMENT RESPONSE; UNIVERSITY HOSPITAL; VISUAL ANALOG SCALE; ADOLESCENT; AGED; ANTAGONISTS AND INHIBITORS; ARTHRITIS, JUVENILE; ARTHRITIS, RHEUMATOID; CHILD; CLINICAL PRACTICE; CONTRAINDICATIONS; DRUG USE; IMMUNOLOGY; MIDDLE AGED; PATIENT SELECTION; PRESCRIPTION; SEVERITY OF ILLNESS INDEX; SPONDYLARTHROPATHIES; TIME; TREATMENT OUTCOME; TREATMENT REFUSAL; TRENDS; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE; ARTHRITIS, RHEUMATOID; CHILD; DRUG PRESCRIPTIONS; DRUG UTILIZATION REVIEW; FEMALE; FRANCE; HUMANS; IMMUNOLOGIC FACTORS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PATIENT SELECTION; PRACTICE PATTERNS, PHYSICIANS'; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SPONDYLARTHROPATHIES; TIME FACTORS; TREATMENT OUTCOME; TREATMENT REFUSAL; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84944409448     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. ROUX CH, SARAUX A, Le BIHAN E et al.: Rheumatoid arthritis and spondyloarthropathies: geographical variations in prevalence in France. J Rheumatol 2007; 34: 117-22.
2. SARAUX A, GUILLEMIN F, GUGGENBUHL P et al.: Prevalence of spondyloarthropathies in France: 2001. Ann Rheum Dis 2005; 64: 1431-5.
3. GUILLEMIN F, SARAUX A, GUGGENBUHL P et al.: Prevalence of rheumatoid arthritis in France: 2001. Ann Rheum Dis 2005; 64: 1427-30.
4. SOLAU-GERVAIS E, ROBIN C, GAMBERT C et al.: Prevalence and distribution of juvenile idiopathic arthritis in a region of Western France. Joint Bone Spine 2010; 77: 47-9.
5. van den BERG R, STANISLAWSKA-BIERNAT E, van der HEIJDE DM: Comparison of recommendations for the use of anti-tumour necrosis factor therapy in ankylosing spondylitis in 23 countries worldwide. Rheumatology (Oxford) 2011; 50: 2270-7.
6. ZOCHLING J, van der HEIJDE D, BURGOSVARGAS R et al.; 'aSSeSSment in aS' internationaL working group; european League againSt rheumatiSm: ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2006; 65: 442-52.
7. SAAG KG, TENG GG, PATKAR NM et al.: American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008; 59: 762-84.
8. SINGH JA, FURST DE, BHARAT A et al.: 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012; 64: 625-39.
9. CURTIS JR, JAIN A, ASKLING J et al.: A comparison of patient characteristics and outcomes in selected European and U.S. rheumatoid arthritis registries. Semin Arthritis Rheum 2010; 40: 2-14.
10. CAPORALI R, SARZI-PUTTINI P, ATZENI F et al.: Switching TNF-alpha antagonists in rheumatoid arthritis: the experience of the LORHEN registry. Autoimmun Rev 2010; 9: 465-9.
11. PEASE C, POPE JE, THORNE C et al.: Canadian variation by province in rheumatoid arthritis initiating anti-tumor necrosis factor therapy: results from the optimization of adalimumab trial. J Rheumatol 2010; 37: 2469-74.
12. FAUTREL B, FLIPO RM, SARAUX A: Eligibility of rheumatoid arthritis patients for anti-TNF-alpha therapy according to the 2005 recommendations of the French and British Societies for Rheumatology. Rheumatology (Oxford) 2008; 47: 1698-703.
13. SARAUX A, DEVAUCHELLE-PENSEC V, ENGERRAN L, FLIPO RM: Most rheumatologists are conservative in active rheumatoid arthritis despite methotrexate therapy: results of the PRISME survey. J Rheumatol 2006; 33: 1258-65.
14. PHAM T, FAUTREL B, DERNIS E et al.: Recommendations of the French Society for Rheumatology regarding TNF-alpha antagonist therapy in patients with ankylosing spondylitis or psoriatic arthritis: 2007 update. Joint Bone Spine 2007; 74: 638-46.
15. FAUTREL B, PHAM T, MOUTERDE G et al.: Recommendations of the French Society for Rheumatology regarding TNF alpha antagonist therapy in patients with rheumatoid arthritis. Joint Bone Spine 2007; 74: 627-37.
16. van GESTEL AM, HAAGSMA CJ, van RIEL PLCM: Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis Rheum 1998; 41: 1845-50.
17. GARRETT S, JENKINSON T, KENNEDY LG, WHITELOCK H, GAISFORD P, CALIN A: A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994; 21: 2286-91.
18. ARNETT FC, EDWORTHY SM, BLOCH DA et al.: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24.
19. DOUGADOS M, van der LINDEN S, JUHLIN R et al.: The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum 1991; 34: 1218-27.
20. PETTY RE, SOUTHWOOD TR, BAUM J et al.: Revision of the proposed classification criteria for juvenile idiopathic arthritis: Durban,1997. J Rheumatol 1998; 25: 1991-4.
21. GUILLEMIN F, BRAINçON S, POUREL J: Measurement of the functional capacity in rheumatoid polyarthritis: a French adaptation of the Health Assessment Questionnaire (HAQ)]. Rev Rhum Mal Osteoartic 1991; 58: 459-65.
22. POUCHOT J, RUPERTO N, LEMELLE I et al.: Paediatric Rheumatology International Trials Organisation. French Study Group for Quality of Life in Rheumatology. The French version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ). Clin Exp Rheumatol 2001; 19 (Suppl. 23): S60-5.
23. PERNEGER TV, LEPLEGE A, ETTER JF, ROUGEMONT A: Validation of a Frenchlanguage version of the MOS 36-Item Short Form Health Survey (SF-36) in young healthy adults. J Clin Epidemiol 1995; 48: 1051-60.
24. LEPLEGE A, ECOSSE E, VERDIER A, PERNEGER TV: The French SF-36 Health Survey: translation, cultural adaptation and preliminary psychometric evaluation. J Clin Epidemiol 1998; 51: 1013-23.
25. GEENS E, GEUSENS P, VANHOOF J et al.: Belgian rheumatologists' perception on eligibility of RA patients for anti-TNF treatment matches more closely Dutch rather than Belgian reimbursement criteria. Rheumatology (Oxford) 2009; 48: 546-50.
26. YEE CS, FILER A, PACE A, DOUGLAS K, SITUNAYAKE D, ROWE IF; weSt midLandS rheumatoLogy ServiceS and training committee: The prevalence of patients with rheumatoid arthritis in the West Midlands fulfilling the BSR criteria for anti-tumour necrosis factor therapy: an out-patient study. Rheumatology (Oxford) 2003; 42: 856-9.
27. HYRICH KL, LUNT M, WATSON KD, SYMMONS DP, SILMAN AJ; BritiSh Society for rheumatoLogy BioLogicS regiSter: Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second antitumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study. Arthritis Rheum 2007; 56: 13-20.
28. YAZICI Y, SHI N, JOHN A: Utilization of biologic agents in rheumatoid arthritis in the United States: analysis of prescribing patterns in 16,752 newly diagnosed patients and patients new to biologic therapy. Bull NYU Hosp Jt Dis 2008; 66: 77-85.
29. DeWITT EM, LIN L, GLICK HA, ANSTROM KJ, SCHULMAN KA, REED SD: Pattern and predictors of the initiation of biologic agents for the treatment of rheumatoid arthritis in the United States: an analysis using a large observational data bank. Clin Ther 2009; 31: 1871-80; discussion 1858.
30. HETLAND ML, CHRISTENSEN IJ, TARP U et al.; aLL departmentS of rheumatoLogy indenmark: Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum 2010; 62: 22-32.
31. KIEVIT W, FRANSEN J, ADANG EM et al.: Long-term effectiveness and safety of TNFblocking agents in daily clinical practice: results from the Dutch Rheumatoid Arthritis Monitoring register. Rheumatology (Oxford) 2011; 50: 196-203.
32. ARENDS S, BROUWER E, van der VEER E et al.: Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study. Arthritis Res Ther 2011; 13: R94.
33. LORD PA, FARRAGHER TM, LUNT M, WATSON KD, SYMMONS DP, HYRICH KL; BSr BioLogicS regiSter: Predictors of response to anti-TNF therapy in ankylosing spondylitis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford) 2010; 49: 563-70.
34. BRAUN J, SIEPER J: Remission and possible discontinuation of biological therapy in axial spondyloarthritis. Clin Exp Rheumatol 2013; 31 (Suppl. 78): S33-6
35. SONG IH, HAIBEL H, PODDUBNYY D, BRAUN J, SIEPER J: Withdrawal of biologic therapy in axial spondyloarthritis: the experience in early disease. Clin Exp Rheumatol 2013; 31 (Suppl. 78): S37-42.
36. RAMíREZ-HERRáIZ E, ESCUDERO-VILAPLANA V, ALAñóN-PLAZA E et al.: Efficiency of adalimumab, etanercept and infliximab in rheumatoid arthritis patients: dosing patterns and effectiveness in daily clinical practice. Clin Exp Rheumatol 2013; 31: 559-65.
37. BERESNIAK A, BAERWALD C, ZEIDLER H et al.: Cost-effectiveness simulation model of biologic strategies for treating to target rheumatoid arthritis in Germany. Clin Exp Rheumatol 2013; 31: 400-8.
38. CECCARELLI F, PERRICONE C, TROTTA F et al.: Remission in early, aggressive rheumatoid arthritis: a multicentre prospective observational Italian study ARPA (Artrite Reumatoide Precoce Aggressiva). Clin Exp Rheumatol 2013; 31: 341-9.
39. RICHETTE P, TUBACH F, BREBAN M et al.: Psoriasis and phenotype of patients with early inflammatory back pain. Ann Rheum Dis 2013; 72: 566-71.